Skip to content
MarketScale
‹ Back to IndustriesHealthcare

How Insurance Payers Allying With Providers Can Lead to Efficient Health Outcomes

Improving healthcare Insurance payers greatly influence outcomes and patient experiences and the subject has become a hot-button issue, especially as the costs of healthcare continues to escalate. In an industry that accounted for nearly 18 percent of the U.S. GDP in 2021, the insurance payers’ role in improving healthcare access, experience, and outcomes is crucial….

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from Highway to Health on MarketScale.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

Improving healthcare Insurance payers greatly influence outcomes and patient experiences and the subject has become a hot-button issue, especially as the costs of healthcare continues to escalate. In an industry that accounted for nearly 18 percent of the U.S. GDP in 2021, the insurance payers’ role in improving healthcare access, experience, and outcomes is crucial. The timely discourse surrounding their impact, responsibilities, and potential for bridging gaps in the healthcare system is more significant than ever.

What is the role of insurance payers in improving healthcare? How are insurance companies responding to the call for more accessible and effective healthcare? How can they collaborate with providers, patients, and technology innovators to deliver better outcomes?

These critical questions were answered in an episode of “Highway to Health,” hosted by healthcare advocate and podcast host, David Kemp who interviewed Dr. Samrat Ambewadikar, MD, Regional Vice President and Medical Director of National Accounts at Anthem, one of the largest insurance companies in the country. The discussion delved into the payer’s perspective of healthcare, their efforts to be an ally to all stakeholders, and their vision for the future of health.

The main points of conversation between Kemp and Ambewadikar included:

  • The responsibility and role of insurance payers in improving healthcare access and outcomes
  • The potential for digital health solutions and software innovations in aiding providers
  • The importance of self-care, physical activity, and healthy lifestyle habits among healthcare executives

Dr. Ambewadikar is a respected figure in the healthcare industry with years of experience in strategic roles at Anthem, one of the largest health insurance providers in the United States. He is an advocate for physical fitness, nutrition, and self-care, leveraging these principles in his personal life and professional practice. His insights stem from a blend of medical expertise and executive leadership in the payer sector of healthcare.

Highway to Health

Part of this channel

Highway to Health

Healthcare innovation conversations for executives and technology buyers.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus has made a $450 million deal with Alkeus to acquire two assets, including a phase 3 oral Stargardt program and a post-injection antiseptic. The focus now moves to clinical trial operations, chemistry manufacturing and controls, and plans for specialty distribution. These acquisitions aim to expand Tarsus' retina programs.

  • 01Tarsus acquired a phase 3 oral Stargardt asset and a post-injection antiseptic for $450 million.
  • 02The acquisitions focus on enhancing clinical trial operations and chemistry manufacturing controls.
  • 03Plans for future specialty distribution of the acquired assets are in place.

Aug 29, 2026

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

The FDA has released a generative AI discussion paper proposing a shift towards competency-style evaluation and increased postmarket monitoring in the healthcare industry. This move may lead vendors and hospital buyers to prioritize developing robust testing protocols for AI applications. The focus is on ensuring reliable and safe AI implementation in medical technologies.

  • 01The FDA's discussion paper suggests implementing competency-style evaluation for AI in healthcare.
  • 02There is an emphasis on increased postmarket monitoring for AI applications in the medical field.
  • 03Vendors and hospital buyers are encouraged to focus on developing testing protocols rather than presentations.

Aug 29, 2026

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 is focusing on integrating smart glasses and AI into the purchasing processes for optical retailers and labs. The event is anticipated to attract around 34,000 visitors and feature 950 exhibitors, indicating significant interest in AI imaging workflows and smart-glass innovations. The agenda highlights a future direction towards advanced technology in optical retail and laboratory settings.

  • 01SILMO Paris 2026 will host nearly 34,000 visitors and 950 exhibitors.
  • 02The event focuses on AI imaging workflows and smart-glass innovations for optical retailers and labs.
  • 03Significant interest is shown in integrating advanced technology within optical retail processes.

Aug 29, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512